Navigation Links
Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
Date:3/20/2012

tic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX-594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the r
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... BOSTON , Aug. 28, 2014  Next month, executives ... at three key industry events beginning with Patient-Centered Clinical ... Hotel in Boston , September 4-5. Patient ... , and Aaron Fleishman will share insights on ... how a variety of tactics – from media to mobile ...
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Years Recognizes Breakthrough ... of Heart Disease, ABBOTT PARK, Ill., Oct. 28 ... Innovation Award for its XIENCE V(TM),Everolimus Eluting Coronary Stent ... data, the next-generation drug eluting stent,represents a significant advance ...
... Oct. 28 Volcano Corporation,(Nasdaq: VOLC ), a ... the diagnosis and treatment of coronary and peripheral artery,disease, ... for the,third quarter and first nine months of fiscal ... a conference call to discuss its financial,results and operating ...
... 28 Sirnaomics, Inc., (http://www.sirnaomics.com ) announced ... SBIR,(small business innovation research) grant from National ... Sirnaomics, Inc., a,biopharmaceutical company founded in early ... Technology for novel targeted therapeutic,development. The company,s ...
Cached Biology Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 2Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 3Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 3
(Date:8/29/2014)... the repeated climatic shifts over the last 120,000 ... diversity, a team of researchers led by City ... developed a new biodiversity metric called "phylogeographic endemism." ... genetic variation within species is restricted in geographical ... biology, and 14 other researchers from institutions in ...
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... the prolific bloomer Emiliania huxleyi , can grow ... finding contradicts the common view that E. huxleyi ... supplies of thiamine in the ocean to survive. , ... ocean," says CIFAR Senior Fellow Alexandra Worden , ... CIFAR fellows John Archibald (Dalhousie University), ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... keeper of the world,s shark attack records, is also now ... the sawfish. Distinguished by a long rostrum or "saw" ... its name, the sawfish has become a historical and cultural ... ichthyologist and curator of both the International Shark Attack File ...
... Geosphere , The Geological Society of America,s e-journal, ... multiple fields, including tectonics, oceanography, sedimentology, and paleontology, to ... to 6 million years ago; sedimentation in a piggyback ... Nevada; and a study of the South Balkan extensional ...
... Calif. For their landmark research leading to the ... flood-prone areas worldwide, Julia Bailey-Serres of UC ... David Mackill of the International Rice Research ... U.S. Department of Agriculture (USDA) with the 2008 USDA ...
Cached Biology News:Endangered sawfish focus of national collection and recovery efforts 2December Geosphere media highlights 2December Geosphere media highlights 3UC Riverside rice geneticist receives high honor from US Department of Agriculture 2UC Riverside rice geneticist receives high honor from US Department of Agriculture 3
Recombinant Feline IFN-alpha...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Biology Products: